People · Operator
Named in public records as an officer, director or promoter · active 2007–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2018 |
| Opus Genetics, Inc. | — | Biotechnology | Series B | $46.9M | $160.9M | 2024 |
| Alessa Therapeutics, Inc. | — | Pharma | Series B | $31.6M | $129.5M | 2025 |
| selectIon, Inc. | — | Biotechnology | Series A | $19.6M | $16.1M | 2021 |
| Nerveda Llc | — | Biotechnology | Series A | $18.0M | $141.0M | 2007 |
| RetroSense Therapeutics, LLC | — | Biotechnology | Series A | $6.9M | $164.9M | 2015 |
| Ocuphire Pharma, Inc. | — | Biotechnology | Seed | $3.9M | $94.4M | 2020 |
Cam Gallagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cam Gallagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Ainsworth | 3 | 5 |
| Mina Sooch | 2 | 5 |
| James Manuso | 2 | 4 |
| Bernhard Hoffmann | 2 | 2 |
| David Johnson | 1 | 35 |
| Richard Lim | 1 | 14 |
| Scott L. Glenn | 1 | 9 |
| Michael Foster | 1 | 8 |
| Douglas Crawford | 1 | 8 |
| Alan Colowick | 1 | 7 |
| Peter Parker | 1 | 6 |
| MIN CUI | 1 | 5 |
| Antonius Schuh | 1 | 5 |
| Mark Chin | 1 | 4 |
| Richard Rodgers | 1 | 4 |
| Adam Cohen | 1 | 3 |
| James S. Manuso | 1 | 3 |
| John Maroney | 1 | 3 |
| Steve Zaniboni | 1 | 3 |
| Doug Crawford | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.